Literature DB >> 10737629

Ligand recognition of serine-cysteine amino acid exchanges in transmembrane domain 5 of alpha2-adrenergic receptors by UK 14,304.

V Cockcroft1, H Frang, M Pihlavisto, A Marjamäki, M Scheinin.   

Abstract

Ligand binding of UK 14,304 reveals notable species (i.e., human-rodent) and receptor-subtype differences of alpha2-adrenergic receptors (alpha2-ARs). To study the molecular basis of the selectivity of UK 14,304, we compared a series of conservative serine-cysteine exchange mutants at ligand-accessible positions in transmembrane domain 5 of the human and mouse alpha2A-ARs. UK 14,304 bound with approximately 200-fold higher affinity to the human alpha2A-AR wild-type receptor compared with the human alpha2A-ARSer201 mutant, but only an approximately fivefold difference was seen with the corresponding mouse alpha2A-AR variant. These effects of cysteine-serine exchanges only involved the agonist low-affinity forms of the receptors, as the affinity of [3H]UK 14,304 for the agonist high-affinity receptor populations was not influenced. The apparent affinities of a set of eight structurally diverse alpha2-AR ligands (six agonists and two antagonists) were not influenced significantly by the cysteine-serine exchanges (except for oxymetazoline and yohimbine, with up to nine- and eightfold differences in affinity, respectively). We conclude that position 201 (a) plays a primary role in determining observed subtype/species selectivity of UK 14,304 in competitive antagonist radioligand binding assays and (b) does not determine the subtype selectivity of chlorpromazine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737629     DOI: 10.1046/j.1471-4159.2000.0741705.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Involvement of the first transmembrane segment of human α(2) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine.

Authors:  J M M Laurila; G Wissel; H Xhaard; J O Ruuskanen; M S Johnson; M Scheinin
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.

Authors:  Juha M Peltonen; Tommi Nyrönen; Siegfried Wurster; Marjo Pihlavisto; Anna-Marja Hoffrén; Anne Marjamäki; Henri Xhaard; Liisa Kanerva; Juha-Matti Savola; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

3.  The second extracellular loop of alpha2A-adrenoceptors contributes to the binding of yohimbine analogues.

Authors:  J M M Laurila; H Xhaard; J O Ruuskanen; M J M Rantanen; H K Karlsson; M S Johnson; M Scheinin
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

4.  The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.

Authors:  Richard G W Proudman; Juliana Akinaga; Jillian G Baker
Journal:  Pharmacol Res Perspect       Date:  2022-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.